Its centrality implies that hPMSC therapy may suppress GVHD-driven hyperinflammation by modulating NF-κB activity, thereby reducing TNF-α/IL-1β production and T-cell activation (28, 29). The gene discussed is TNF; the disease is graft versus host disease.